Thank you, Presiding Officer.
I thank the colleagues across the chamber who supported my motion on developing a national Scottish Fontan service and transplant pathway. Because of their support, I am pleased to bring this motion to the chamber this evening.
The motion recognises the life-saving importance of the Fontan procedure for children who are born with complex congenital heart disease, and it calls for a more co-ordinated and sustainable approach to supporting those living with Fontan circulation here, in Scotland.
We are joined by a number of people in the public gallery for whom this subject is an integral part of their lives. I reassure them that these technical issues do not usually happen. I also thank my constituent Nicole Egan, who sadly could not be here tonight. Her tenacity ensured that the debate could take place this evening. Nicole, the attendees who are here tonight and the countless others who will be watching online will know all too well that, for many families, a diagnosis of complex congenital heart disease is the beginning of an incredibly difficult and frightening journey. Parents are faced with uncertainty, difficult decisions and the prospect of their child undergoing major surgery at an exceptionally young age.
For children born with single-ventricle heart conditions, the Fontan procedure can be life saving. It is a remarkable surgical intervention that allows children who might otherwise have had a very limited life expectancy to survive, grow up and experience many of the opportunities that other children take for granted. The procedure works by redirecting oxygen-poor blood returning from the body directly to the lungs, bypassing the heart. That allows oxygen-rich blood to circulate around the body more effectively, significantly improving oxygen levels and, in many cases, improving a child’s energy, physical capability and quality of life.
It is difficult to overstate what that means to families. The Fontan procedure has transformed the prospects of children who are born with some of the most complex forms of congenital heart disease. Children who may once have faced an uncertain future are now growing into teenagers and adults, pursuing education, building relationships, entering employment and planning their futures. We must acknowledge that that is an extraordinary achievement of modern medicine.
However, we must also recognise that the Fontan procedure is a mitigation, not a cure. Living with Fontan circulation brings lifelong medical challenges. The circulation works differently from that of a person with a normal heart, and, over time, that places additional pressure on the heart and other organs. As patients grow older, they can develop serious complications including heart failure, abnormal heart rhythms, blood clots, kidney dysfunction, protein-losing enteropathy, plastic bronchitis and progressive liver disease. Fontan-associated liver disease is a particularly significant concern. The altered circulation increases pressure in the veins, making it more difficult for blood to drain from the liver. That can lead to scarring and, in some cases, more serious liver complications.
Lifelong follow-up is essential. Monitoring can involve blood tests, heart scans, liver imaging, MRI investigations and other specialist assessments. Importantly, that care often requires cardiologists to work alongside liver specialists and other clinical professionals. I stress that it is not an occasional follow-up—it is lifelong, complex and increasingly important as patients reach adulthood.
Although we can consider the Fontan procedure as a success of modern medicine, it has created a new and growing responsibility for our health service. International prevalence data suggest that between 300 and 400 people in Scotland are currently living with Fontan circulation. Improvements in surgical techniques and long-term survival mean that an increasing number of those individuals are now reaching adulthood.
Adult survival rates exceeding between 85 and 90 per cent are encouraging, but they mean that we must prepare for the growing clinical needs of that population. Estimates suggest that between approximately 20 and 30 per cent of people who are living with Fontan circulation may ultimately require consideration for transplantation, potentially involving the heart, liver and, in some circumstances, the lungs. That will present a significant challenge for NHS Scotland.
Scotland does not currently have a dedicated national pathway for failing Fontan circulation and complex congenital heart disease requiring transplantation. As a result, some patients must be referred outside Scotland, most commonly to specialist centres in England. I make it clear that access to specialist expertise wherever it is available is essential, and cross-border arrangements will continue to play an important role. Patients must never be denied the treatment that they need because of geographical boundaries.
However, we must recognise the additional burden that travelling elsewhere in the United Kingdom can place on patients and their families. For someone who is already living with a serious and complex heart condition, travelling long distances outside their own country for specialist appointments, assessments or major treatment can be physically and emotionally exhausting. For families, there can be considerable financial pressures, accommodation costs, time away from work and prolonged periods of separation from their usual support networks.
There are also questions about continuity of care. When treatment involves different health boards, hospitals and clinical teams, ensuring that information is shared effectively and that patients receive consistent follow-up becomes even more important. Those administrative challenges affect people's lives, their families and their experience of healthcare at an already vulnerable time. That is why I believe that Scotland needs to look seriously at developing a national Fontan hub. Scotland is not starting from scratch in that—we already have significant strengths on which to build.
The Scottish adult congenital cardiac service provides an important foundation for specialist congenital heart disease care. We also have established heart transplant infrastructure at the Golden Jubilee national hospital, experienced cardiothoracic surgical teams and the ability to plan and co-ordinate national specialist services. I believe that we should bring those strengths together. A national Fontan hub could provide a co-ordinated approach to lifelong surveillance, early identification of complications, multidisciplinary assessment, risk stratification and transplant planning. It could also help to establish clearer pathways between specialist centres, local hospitals, primary care and transplant services, ensuring that patients receive the right expertise at the right time.
Crucially, a national hub would not mean that every appointment or investigation would have to take place in one hospital, because that would still require many patients to travel long distances, given the size and rurality of Scotland. Instead, the principle should be to provide specialist care as close to home as is clinically appropriate while ensuring that patients can access highly specialised interventions when they need them. Given the relatively small number of patients involved, we should be able to offer that care as locally as possible. For those throughout Scotland, access to specialist expertise should not depend on where they happen to live or how easily they can travel.
We must also consider what happens when a patient undergoes a transplant. Transplantation is not the end of the healthcare journey—it brings its own lifelong requirements, including medication, monitoring, specialist appointments and surveillance for complications. Scotland needs to consider how a formalised shared-care model could support patients following transplantation, particularly those who have received treatment at specialist centres elsewhere in the UK.
Clear arrangements between Scottish services and English transplant centres would help to protect continuity of care, avoid unnecessary duplication and give patients and families confidence that their long-term needs are being properly managed. That is especially important in the context of any future changes to the organisation or provision of specialist health services, and cross-border access must be protected through clear, sustainable arrangements based on clinical need.
Finally, I stress that we must listen to the people who live with these conditions every day. Patients and families understand the realities of Fontan circulation in a way that statistics alone cannot capture, and their experiences should help to shape the services that we develop. The Scottish Government should, therefore, now engage with NHS Scotland, the Scottish adult congenital cardiac service, transplant centres, clinical specialists and affected families to undertake a proper feasibility assessment. That assessment could consider workforce planning, specialist training and long-term financial sustainability.
The Fontan procedure has given thousands of people around the world something that previous generations could not have imagined: the opportunity to survive childhood and live well into adulthood, despite having some of the most complex forms of congenital heart disease. We should celebrate that achievement, but we must recognise the responsibility that comes with it. It cannot be right that the success of life-saving surgery is followed by uncertainty about where patients will receive the specialist care that they need as adults.
We have the clinical expertise, the existing infrastructure and the opportunity to develop a better, more co-ordinated approach in Scotland, and I hope that the Minister for Mental Wellbeing, Public Health, Sport, Alcohol and Drugs will be able to reflect on that in summing up.
18:07